Q4 2024 Journey Medical Corp Earnings Call Transcript
Key Points
- Journey Medical Corp (DERM) reported annual revenue of $56 million in 2024, achieving positive non-GAAP adjusted EBITDA for the sixth consecutive quarter.
- The company successfully launched Emrosi, an oral treatment for rosacea, with FDA approval received on time in November 2024.
- Journey Medical Corp (DERM) has a strong balance sheet with $20.3 million in cash as of December 31, 2024, despite significant one-time payments for Emrosi's regulatory fees.
- Emrosi's Phase 3 clinical results showed superiority against the current oral standard of care, entering a $1 billion plus treatment category.
- The company anticipates significant operating leverage from Emrosi sales, with potential peak annual sales of $200 million in the U.S. and $100 million internationally.
- Total net product revenue in 2024 decreased to $55.1 million from $59.7 million in 2023, primarily due to higher rebate costs and lower unit volumes from legacy products.
- Research and development expenses increased by $2.3 million to $9.9 million in 2024, driven by non-recurring payments related to Emrosi's NDA filing.
- Net loss to common shareholders was $14.7 million for 2024, compared to a net loss of $3.9 million in 2023.
- The company has not yet provided 2025 financial guidance, citing the variability associated with the Emrosi launch.
- Initial commercial payer coverage for Emrosi is limited, with only 20% of commercial lives and 4% of Medicare lives covered, though this is expected to improve over time.
Ladies and gentlemen, thank you for standing by. Good afternoon and welcome to Journey Medical's 2024 Financial Results and Corporate Update Conference Call (Operator Instructions)
I would now like to turn the call over to Jaclyn Jaffe, the Company's Senior Director of Corporate Operations. Please go ahead.
Good afternoon, and thank you for participating in today's conference call. Joining me from Journey Medical's leadership team are Claude Maraoui, Co-Founder, President and Chief Executive Officer; and Joseph Benesch, Chief Financial Officer. Joining for the Q&A portion of the call will be Ramsey Alloush, General Counsel and Corporate Secretary; Dr. Srini Sidgiddi, Vice President of Research and Development; and Louis Donati, Director of Market Access.
During this call, management will be making forward-looking statements, including statements that address, among other things, Journey Medical's expectations for future performance, operational results, financial condition and the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
